|
|
|
|
| Join us for two Outsourced Pharma Capabilities Update sessions featuring leading CDMOs sharing their facilities, timelines, and available capacity for development and manufacturing. The April 21st session focuses on small molecule drug product capabilities, while April 22nd highlights fill-finish technologies including sterile filling, lyophilization, and advanced packaging. Expect short digital presentations to help biopharma companies identify partners that can meet their manufacturing needs. Click to learn more. |
|
|
|
|
| The Art And Science Of Topical Formulations | Video | MedPharm | Chief Scientific Officer Jon Lenn discusses the balance of art and science in topical formulation development, emphasizing advanced skin models for optimized delivery, activity, and product stability. |
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | “I assist C-suite executives to transfer quality from a painful cost center to a competitive asset." It's the type of bold statement that draws one's attention. Chief Editor Louis Garguilo asked David Grote on what his assertion means materially – and how that’s applied to working with CDMOs. Here's their discussion that focuses on a transformation that moves executives from regarding quality as ‘overhead’ to recognizing quality as “an operational element for business advantage.” | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| Advantages Of Localized OSF Production | Article | Thermo Fisher Scientific | Discover how localized OSD development and manufacturing in Europe can help pharmaceutical companies navigate complexity, strengthen supply chains, and scale to meet market demands. |
|
|
| Enabled Form Selection For Oral Drug Products | Webinar | Lonza | Review the role of solid form screening and PBPK modeling to enable accelerated timelines desirable in early-phase drug development. Explore formulation maps for ASDs and key criteria for salt screening. |
|
|
| The Importance Of Tablet Density Uniformity | Article | Natoli Engineering Company, Inc. | Non-uniform density causes many tablet failures. Learn how optimizing your formulation, tablet proportions, and tooling design ensures proper de-aeration for consistent quality. |
|
|
| Targeted Protein Degraders: Transforming Oral Therapeutics | Article | By Rebecca Coutts, Ph.D., PCI Pharma Services | CDMOs play a critical role in TPD development by offering specialized infrastructure and analytical capabilities to support the transition from preclinical research to clinical supply and commercialization. |
|
|
|
|
|
Oral Solid Dose Manufacturing | Alcami | We provide cGMP manufacturing services that scale with your development and approval milestones, ensuring a seamless transition from clinical to commercial supply. |
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
